Joel Beatty
Stock Analyst at Baird
(4.52)
# 297
Out of 5,017 analysts
199
Total ratings
49.38%
Success rate
30.07%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics | Maintains: Outperform | $10 → $7 | $4.25 | +64.71% | 3 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $50 → $67 | $34.41 | +94.71% | 3 | Sep 9, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $3.56 | +68.54% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $16.20 | -44.44% | 6 | Jul 8, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $110 → $145 | $132.69 | +9.28% | 8 | Jun 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $20.06 | +54.54% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $31.62 | -24.10% | 5 | May 16, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $799.56 | -14.95% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $14.98 | +93.59% | 2 | May 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $70 → $66 | $66.06 | -0.09% | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $167 → $155 | $135.14 | +14.70% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $121.15 | +33.72% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $32.17 | +27.45% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $12.25 | +30.61% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $11.87 | +34.79% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $52.34 | +39.47% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $20.40 | +56.86% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $64.97 | +15.44% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $14.12 | -22.10% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.99 | +251.76% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $52.45 | +23.93% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $32.02 | +124.86% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $1.63 | +14,623.93% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.27 | +254.33% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $9.72 | +157.20% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.60 | +1,392.29% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $15.20 | +84.21% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.83 | +774.32% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.71 | -26.90% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.49 | +2,853.02% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $36.25 | +60.00% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $26.77 | -10.35% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $19.39 | -7.17% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.26 | +165.49% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.86 | +377.82% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $464.95 | -62.36% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $5.23 | +167.69% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $21.96 | +391.80% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $70.59 | +10.50% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $16.43 | +508.83% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $19.17 | +525.98% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $3.06 | +14,605.88% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.72 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $8.62 | +74.01% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.62 | +19,339.49% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $9.93 | +91.34% | 3 | Nov 10, 2017 |
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $4.25
Upside: +64.71%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50 → $67
Current: $34.41
Upside: +94.71%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $3.56
Upside: +68.54%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $16.20
Upside: -44.44%
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110 → $145
Current: $132.69
Upside: +9.28%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $20.06
Upside: +54.54%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $31.62
Upside: -24.10%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $799.56
Upside: -14.95%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $14.98
Upside: +93.59%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $66.06
Upside: -0.09%
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $135.14
Upside: +14.70%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $121.15
Upside: +33.72%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $32.17
Upside: +27.45%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $12.25
Upside: +30.61%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $11.87
Upside: +34.79%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $52.34
Upside: +39.47%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $20.40
Upside: +56.86%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $64.97
Upside: +15.44%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $14.12
Upside: -22.10%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.99
Upside: +251.76%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $52.45
Upside: +23.93%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $32.02
Upside: +124.86%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $1.63
Upside: +14,623.93%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.27
Upside: +254.33%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $9.72
Upside: +157.20%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.60
Upside: +1,392.29%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $15.20
Upside: +84.21%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $1.83
Upside: +774.32%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.71
Upside: -26.90%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.49
Upside: +2,853.02%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $36.25
Upside: +60.00%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $26.77
Upside: -10.35%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $19.39
Upside: -7.17%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.26
Upside: +165.49%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.86
Upside: +377.82%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $464.95
Upside: -62.36%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $5.23
Upside: +167.69%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $21.96
Upside: +391.80%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $70.59
Upside: +10.50%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $16.43
Upside: +508.83%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $19.17
Upside: +525.98%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $3.06
Upside: +14,605.88%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $2.72
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $8.62
Upside: +74.01%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.62
Upside: +19,339.49%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $9.93
Upside: +91.34%